Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral nifedipine versus intravenous labetalol for severe hypertension in pregnancy
PACTR202503835469014Not yet recruiting
- Sponsor
- Salman Abdulkadir
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in maternal hypertension (HDP) comparing Oral nifedipine with Intravenous labetalol (2 arms). Primary endpoints: Time to achieve target blood pressure and Minimum number of antihypertensive doses required. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
nifedipinelabetalol
03
Conditions
maternal hypertension (HDP)
Beyond the preview
Go deeper on PACTR202503835469014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503835469014.